Carna Biosciences, Inc. provided consolidated earnings guidance for the fiscal year ending December 31, 2020. For the fiscal year, the company expects to report net sales of JPY 1,036 million, operating loss of JPY 1,779 million, ordinary loss of JPY 1,794 million, loss attributable to owners of parent of JPY 1,822 million, and loss per share of JPY 156.45.